Last reviewed · How we verify
NCT07168993: BA-004
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
NA trial testing Standard medical treatment in Lung Cancer (Diagnosis) in 2,063 participants. Currently enrolling.
1 April 2029
Quick facts
| Lead sponsor | bioAffinity Technologies Inc. |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 2,063 |
| Start date | 25 February 2026 |
| Primary completion | 1 April 2029 |
| Estimated completion | 1 July 2029 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- Standard medical treatment — full drug profile →
- Standard medical treatment — full drug profile →
Conditions studied
- Lung Cancer (Diagnosis) — all drugs for Lung Cancer (Diagnosis) →
Sponsor
bioAffinity Technologies Inc. — full company profile →
Who can join
Adults 50 to 80, any sex, with Lung Cancer (Diagnosis). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Evaluate FlowPath Lung Diagnostic Test of Sputum Samples to Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, \>6 to \<30 mm in Diameter, Determined by LDCT.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Sputum Liquid Biopsy for Lung Cancer Screening, Diagnosis, Subtyping, Surveillance, Response Prediction, and Prognostication: A Scoping Review.
Rehman A, Awais M, Baloch HNUA, Leghari MO, et al · · 2026 · PMID 42201023 · DOI 10.3390/medsci14020231
Verify or expand the search:
- PubMed search for NCT07168993
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Standard medical treatment
Trials testing the same drug.
- NCT07218198 — Clinical Decision Support Tool for the Treatment of Uncontrolled Hypertension · NA · not yet recruiting
- NCT07397117 — Comparing Ultrasound-Guided Transgluteal Nerve Block to Standard Care · NA · recruiting
- NCT07506499 — Cardiac Rehabilitation in Decompensated Heart Failure · NA · recruiting
- NCT07445035 — Effects of Mobilization Using a Powered Lower-limb Exoskeleton With Prolonged Mechanical Ventilation · NA · not yet recruiting
- NCT07471256 — Neuronavigation-assisted Stereotactic Minimally Invasive Puncture With Tenecteplase for Acute Lobar Intracerebral Hemorr · Phase 3 · not yet recruiting
Other recruiting trials for Lung Cancer (Diagnosis)
Currently open trials in the same condition.
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07510724 — Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab · recruiting
- NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
- NCT07241182 — Antrodia Cinnamomea Extract Effects on Lung Cancer Patients' Quality of Life During Chemotherapy · NA · recruiting
- NCT07231159 — Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots · recruiting
Other bioAffinity Technologies Inc. trials
Trials by the same sponsor.
- NCT03837600 — Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07168993 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by bioAffinity Technologies Inc.
- Last refreshed: 18 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07168993.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing